Chicago, IL, September 21, 2026 — Sus Clinicals, Inc.® has received U.S. Food & Drug Administration authorization to commercialize cancer cell lines derived from the Company’s proprietary Oncopig®. Following a…
Read article LOGAN, UT and CINCINNATI, OH, April 7, 2026 – IBEX Preclinical Research, a leading med tech CRO for preclinical surgical studies across a variety of laboratory animal species, and Sus…
Read article WEST LAFAYETTE, Ind.–(BUSINESS WIRE)–MED Institute, a leader in pre-clinical and clinical medical product development services, is proud to announce a strategic collaboration with Sus Clinicals, a pioneering provider of genetic-modified…
Read article
Experienced Pharmaceuticals and Oncology Executive to Assume Leadership Role Cincinnati, OH and Boston, MA, July 29, 2024 — Sus Clinicals, Inc.® announced today that Jessicca M. Rege, Ph.D. has been…
Read article Sus Clinicals, Inc. announced today that Dr. Lawrence Schook has been elected to the Company’s Board of Directors
Read article
Funding will support breakthrough work against an aggressive form of liver cancer
Read articleDr. Auro Nair brings over three decades of experience in life sciences and biomedical research
Read article Top experts to advise Company on scientific priorities and innovation strategies
Read articleJeff Sinclair brings 30+ years of experience in strategy, operations and organization design
Read articleGrant of Enforcement Discretion Supports Commercial Launch
Read article